Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hepato-Biliary-Pancreatic Sciences
Published in: Journal of Hepato-Biliary-Pancreatic Sciences 1/2011

01-01-2011 | Original article

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer

Authors: Koji Kitamura, Etsuro Hatano, Tatsuya Higashi, Satoru Seo, Yuji Nakamoto, Masato Narita, Kojiro Taura, Kentaro Yasuchika, Takashi Nitta, Kenya Yamanaka, Ryuichiro Doi, Iwao Ikai, Shinji Uemoto

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 1/2011

Login to get access

Abstract

Background

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is used in the differential diagnosis and staging of extrahepatic bile duct cancer (EBDC), but its prognostic value has not been fully elucidated. In this study, we investigated the prognostic value of FDG-PET in EBDC patients.

Methods

The study included 73 consecutive patients with EBDC, of whom 48 underwent surgical resection for EBDC. The effects of clinicopathological factors including the standardized uptake value (SUV) of the primary lesion and lymph node metastasis detected by FDG-PET (PET-N) on overall survival were evaluated.

Results

In all 73 patients, multivariate analysis showed that surgical resection (risk ratio 2.5, 95% confidence interval [CI] 1.17–5.35, P = 0.018) and the SUV (2.0, 1.07–3.91, P = 0.030) were independent predictors of survival. In the 48 patients who underwent surgical resection, multivariate analysis revealed that perineural invasion (risk ratio 3.2, 95% CI 1.28–7.93, P = 0.012), pathologic lymph node metastasis (3.4, 1.27–9.17, P = 0.015), and PET-N (4.0, 1.10–15.25, P = 0.036) were independent predictors of overall survival. In the 25 patients without surgical resection, the SUV showed a significant relationship with overall survival (P = 0.014).

Conclusion

Our data suggest that the SUV of the primary lesion is a useful prognostic factor in patients with EBDC, and the prognosis for patients with PET-N remains very poor despite surgical resection.
Literature
1.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed
2.
3.
Yee K, Sheppard BC, Domreis J, Blanke CD. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park). 2002;16(7):939–46, 949 (discussion 949–50, 952–3, 956–7).
4.
Daines WP, Rajagopalan V, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 2. Oncology (Williston Park). 2004;18(8):1049–59. (discussion 1060, 1065–6, 1068).
5.
de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–78.CrossRefPubMed
6.
Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498–501.CrossRefPubMed
7.
Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39(5):883–917.CrossRefPubMed
8.
Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35–46.CrossRefPubMed
9.
Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029–35.CrossRefPubMed
10.
Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28(3):700–6.CrossRefPubMed
11.
Widjaja A, Mix H, Wagner S, Graz KF, van den Hoff J, Petrich T, et al. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis. Z Gastroenterol. 1999;37(8):731–3.PubMed
12.
Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol. 2008;23(5):759–65.CrossRefPubMed
13.
Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.CrossRefPubMed
14.
Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29(8):1047–54.CrossRefPubMed
15.
Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90–7.CrossRefPubMed
16.
Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed
17.
Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30(9):1736–41.CrossRefPubMed
18.
Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31(6):1256–63.CrossRefPubMed
19.
Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma, 2nd English edn. Tokyo: Kanehara; 2004.
20.
Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19–22.CrossRefPubMed
21.
Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38(9):1337–44.PubMed
22.
Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769–77.CrossRefPubMed
23.
Furukawa H, Ikuma H, Asakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100(6):494–9.CrossRefPubMed
24.
Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22(12):1277–85.CrossRefPubMed
25.
Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed
26.
Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86(4):512–6.CrossRefPubMed
27.
Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18(4):425–8.CrossRefPubMed
28.
Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26(5):1335–53.CrossRefPubMed
29.
Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145–51.CrossRefPubMed
30.
Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31(10):1175–9.CrossRefPubMed
31.
Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70(5):358–65.CrossRefPubMed
32.
Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405–11.CrossRefPubMed
33.
Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241(5):703–12. (discussion 12–4).CrossRefPubMed
34.
Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):108–16.CrossRefPubMed
35.
Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233(3):385–92.CrossRefPubMed
36.
Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15(1):41–54.CrossRefPubMed
37.
Nakamoto Y, Chang AE, Zasadny KR, Wahl RL. Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. Mol Imaging Biol. 2002;4(2):161–9.CrossRefPubMed
38.
Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89(10):1260–7.CrossRefPubMed
39.
Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240(1):95–101.CrossRefPubMed
40.
Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103(6):1210–6.CrossRefPubMed
Metadata
Title
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer
Authors
Koji Kitamura
Etsuro Hatano
Tatsuya Higashi
Satoru Seo
Yuji Nakamoto
Masato Narita
Kojiro Taura
Kentaro Yasuchika
Takashi Nitta
Kenya Yamanaka
Ryuichiro Doi
Iwao Ikai
Shinji Uemoto
Publication date
01-01-2011
Publisher
Springer Japan
Published in
Journal of Hepato-Biliary-Pancreatic Sciences / Issue 1/2011
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-010-0293-1

Other articles of this Issue 1/2011

Journal of Hepato-Biliary-Pancreatic Sciences 1/2011 Go to the issue

Image of interest

Sister Mary Joseph’s nodule derived from pancreatic cancer

Topics

Autologous bone marrow cell infusion therapy for liver cirrhosis patients

Technical note

Robotic right hepatectomy for giant hemangioma in a Jehovah’s Witness

Original article

Duodenum-preserving versus pylorus-preserving pancreatic head resection for benign and premalignant lesions

Original Article

Prediction and management of a low-lying costal arch which restricts the operative working space during laparoscopic cholecystectomy

Original article

Persistent biliary dilatation and stenosis in postoperative congenital choledochal cyst